BAJAJ BROKING

Notification close image
No new Notification messages
card image
Crizac IPO is Open!
Apply for the Crizac IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

16725

532983

RPGLIFE

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

RPG LIFE SCIENCES LTD performance

Today’s low

Today’s high

₹ 2468.00 ₹ 2543.50
₹ 2524.60

52 week low

52 week high

₹ 1539.95 ₹ 2974.95
₹ 2524.60

Open Price

₹ 2500.00

Prev. Close

₹ 2498.50

Volume (Shares)

5932.00

Total traded value

₹ 149.75

Upper Circuit

₹ 2998.20

Lower Circuit

₹ 1998.80

info

RPG LIFE SCIENCES LTD Share Price Update

As of the latest trading session, RPG LIFE SCIENCES LTD share price is currently at ₹ 2526.1, which is up by ₹ 27.60 from its previous closing. Today, the stock has fluctuated between ₹ 2468.00 and ₹ 2543.50. Over the past year, RPG LIFE SCIENCES LTD has achieved a return of 57.46 %. In the last month alone, the return has been 16.74 %. Read More...

Investment Returns

Over 1 Month 16.74% Over 3 Months 12.37% Over 6 Months 15.44% Over 1 Year 57.46%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

RPG LIFE SCIENCES LTD fundamentals


  • Market cap (Cr)

    4,172.00

  • P/E Ratio (TTM)

    22.59

  • Beta

    0.90

  • Book Value / share

    320.77

  • Return on equity

    25.53%

  • EPS (TTM)

    69.88

  • Dividend yield

    0.80%

  • Net profit/quarter (Cr)

    117.35

info icon alternate text
  • Market cap (Cr)

    4,166.80

  • P/E Ratio (TTM)

    22.59

  • Beta

    0.81

  • Book Value / share

    320.77

  • Return on equity

    25.53%

  • EPS (TTM)

    69.88

  • Dividend yield

    0.80%

  • Net profit/quarter (Cr)

    117.35

info icon alternate text

RPG LIFE SCIENCES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 143.09
Operating Expense 123.15
Net Profit 117.35
Net Profit Margin (%) 82.01
Earnings Per Share (EPS) 70.96
EBITDA 140.45
Effective Tax Rate (%) 13.00
Particulars DEC 2024 (Values in Cr)
Revenue 172.71
Operating Expense 129.13
Net Profit 34.93
Net Profit Margin (%) 20.22
Earnings Per Share (EPS) 21.12
EBITDA 52.47
Effective Tax Rate (%) 25.50
Particulars SEP 2024 (Values in Cr)
Revenue 172.21
Operating Expense 131.76
Net Profit 4.20
Net Profit Margin (%) 2.43
Earnings Per Share (EPS) 2.54
EBITDA 20.57
Effective Tax Rate (%) 72.16
Particulars JUN 2024 (Values in Cr)
Revenue 165.42
Operating Expense 131.79
Net Profit 26.76
Net Profit Margin (%) 16.17
Earnings Per Share (EPS) 16.18
EBITDA 41.44
Effective Tax Rate (%) 25.66
Particulars MAR 2024 (Values in Cr)
Revenue 126.99
Operating Expense 110.90
Net Profit 13.24
Net Profit Margin (%) 10.42
Earnings Per Share (EPS) 8.01
EBITDA 22.36
Effective Tax Rate (%) 25.36
Particulars MAR 2025 (Values in Cr)
Revenue 653.43
Operating Expense 515.83
Net Profit 183.24
Net Profit Margin (%) 28.04
Earnings Per Share (EPS) 110.80
EBITDA 254.93
Effective Tax Rate (%) 21.31
Particulars MAR 2024 (Values in Cr)
Revenue 582.05
Operating Expense 471.42
Net Profit 87.66
Net Profit Margin (%) 15.06
Earnings Per Share (EPS) 53.01
EBITDA 135.36
Effective Tax Rate (%) 25.61
Particulars MAR 2023 (Values in Cr)
Revenue 512.81
Operating Expense 425.93
Net Profit 67.64
Net Profit Margin (%) 13.19
Earnings Per Share (EPS) 40.90
EBITDA 107.49
Effective Tax Rate (%) 26.22
Particulars MAR 2022 (Values in Cr)
Revenue 440.16
Operating Expense 369.97
Net Profit 51.48
Net Profit Margin (%) 11.69
Earnings Per Share (EPS) 31.13
EBITDA 89.35
Effective Tax Rate (%) 29.64
Particulars MAR 2021 (Values in Cr)
Revenue 389.14
Operating Expense 336.47
Net Profit 40.00
Net Profit Margin (%) 10.27
Earnings Per Share (EPS) 24.19
EBITDA 70.84
Effective Tax Rate (%) 25.34
Particulars MAR 2025 (Values in Cr)
Book Value / Share 320.80
ROE % 25.53
ROCE % 32.28
Total Debt to Total Equity 0.00
EBITDA Margin 26.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 226.67
ROE % 25.69
ROCE % 34.25
Total Debt to Total Equity 0.00
EBITDA Margin 23.43
Particulars MAR 2023 (Values in Cr)
Book Value / Share 186.00
ROE % 24.01
ROCE % 32.15
Total Debt to Total Equity 0.00
EBITDA Margin 21.12
Particulars MAR 2022 (Values in Cr)
Book Value / Share 154.66
ROE % 21.80
ROCE % 30.57
Total Debt to Total Equity 0.01
EBITDA Margin 20.50
Particulars MAR 2021 (Values in Cr)
Book Value / Share 130.88
ROE % 20.36
ROCE % 26.41
Total Debt to Total Equity 0.03
EBITDA Margin 18.46
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 139.61
Total Assets 657.81
Total Liabilities 657.81
Total Equity 530.53
Share Outstanding 16539015
Price to Book Ratio 7.10
Return on Assets (%) 27.85
Return on Capital (%) 34.54
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 36.47
Total Assets 512.87
Total Liabilities 512.87
Total Equity 374.85
Share Outstanding 16539015
Price to Book Ratio 6.75
Return on Assets (%) 17.09
Return on Capital (%) 23.39
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 57.04
Total Assets 419.35
Total Liabilities 419.35
Total Equity 307.60
Share Outstanding 16539015
Price to Book Ratio 3.74
Return on Assets (%) 16.12
Return on Capital (%) 21.99
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 70.26
Total Assets 344.61
Total Liabilities 344.61
Total Equity 255.77
Share Outstanding 16539015
Price to Book Ratio 3.62
Return on Assets (%) 14.93
Return on Capital (%) 20.1
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 40.75
Total Assets 303.39
Total Liabilities 303.39
Total Equity 216.45
Share Outstanding 16539015
Price to Book Ratio 2.96
Return on Assets (%) 13.18
Return on Capital (%) 18.36
Particulars MAR 2025 (Values in Cr)
Net Income 232.88
Cash from Operations 130.61
Cash from Investing -41.80
Cash from Financing -27.08
Net change in Cash 8.98
Free Cash Flow 166.64
Particulars MAR 2024 (Values in Cr)
Net Income 117.84
Cash from Operations 123.67
Cash from Investing -79.15
Cash from Financing -20.31
Net change in Cash -5.10
Free Cash Flow 192.90
Particulars MAR 2023 (Values in Cr)
Net Income 91.68
Cash from Operations 116.05
Cash from Investing -105.81
Cash from Financing -17.12
Net change in Cash -32.11
Free Cash Flow 148.78
Particulars MAR 2022 (Values in Cr)
Net Income 73.17
Cash from Operations 83.60
Cash from Investing -34.66
Cash from Financing -13.51
Net change in Cash 16.58
Free Cash Flow 107.55
Particulars MAR 2021 (Values in Cr)
Net Income 53.58
Cash from Operations 66.60
Cash from Investing -7.96
Cash from Financing -10.49
Net change in Cash 39.82
Free Cash Flow 75.11
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 35.97 27.46 1.96 275.65 34.11 / 77.70
BLISS GVS PHARMA LTD 155.65 19.46 1.56 1640.09 101.15 / 184.95
CIPLA LTD 1515.95 23.79 3.92 122444.47 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 330.25 12.64 2.67 971.96 163.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 3351.40 64.96 29.09 56774.74 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 35.97 35.97 5.68 275.65 34.11 / 77.70
AMRUTAJAN HEALTH LTD 724.50 41.21 6.41 2094.58 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8898.25 127.08 28.87 22245.63 6171.25 / 10653.05
BLISS GVS PHARMA LTD 155.65 23.76 1.54 1640.09 101.15 / 184.95

RPG LIFE SCIENCES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2522.50 0.96 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 2476.80
  • 26 Days 2339.60
  • 10 Days 2435.90
  • 50 Days 2277.70
  • 12 Days 2420.40
  • 100 Days 2238.80
  • 20 Days 2368.10
  • 200 Days 2168.40
2536.13 PIVOT

First Support

2487.27

First Resistance

2584.67

Second Support

2438.73

Second Resistance

2633.53

Third Support

2389.87

Third Resistance

2682.07

RSI

69.47

ADX

47.18

MACD

79.33

Williams % R

-12.65

Commodity Channel Index (CCI)

135.39

Date

2025-07-01

Week

9200.00

Same Day

12568.00

Month

10966.00

1 Year

0.89

3 Year

0.69

Over 1 Month

16.74%

down

Over 1 Year

57.46%

down

Over 3 Months

12.37%

down

Over 3 Years

65.82%

down

Over 6 Months

15.44%

down

Over 5 Years

57.12%

down

RPG LIFE SCIENCES LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
19.45%
Promoter Holdings
72.95%
FII
1.45%
DII
6.14%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Nucleus Life Trust (mr. Harsh Vardhan Goenka Is A Trustee) 8920831.0 (53.94%) Shareholding of Promoter and Promoter Group
Ektara Enterprises Llp 2575494.0 (15.57%) Shareholding of Promoter and Promoter Group
Stel Holdings Limited 525369.0 (3.18%) Shareholding of Promoter and Promoter Group
Authum Investment And Infrastructure Limited 333473.0 (2.02%) Public Shareholding
Quant Mutual Fund - Quant Active Fund 326816.0 (1.98%) Public Shareholding
Mirae Asset Multicap Fund 184699.0 (1.12%) Public Shareholding
Harsh Vardhan Goenka 26915.0 (0.16%) Shareholding of Promoter and Promoter Group
Mala Goenka 8747.0 (0.05%) Shareholding of Promoter and Promoter Group
Carniwal Investments Limited 6500.0 (0.04%) Shareholding of Promoter and Promoter Group
Citibank N A Jt Ac Sakina Asgarali Morbiwala Nooruddin A Morbiwala 150.0 (0.0%) Public Shareholding
Vayu Associates Llp 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Swallow Associates Llp 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Sofreal Mercantrade Pvt Ltd 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Malabar Coastal Holdings Llp 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Atlantus Dwellings And Infrastructure Llp 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Chattarpati Apartments Llp 362.0 (0.0%) Shareholding of Promoter and Promoter Group
Summit Securities Limited 398.0 (0.0%) Shareholding of Promoter and Promoter Group
Instant Holdings Limited 598.0 (0.0%) Shareholding of Promoter and Promoter Group
Rg Family Trust (mr. Anant Vardhan Goenka Is A Trustee) 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Navya Goenka Trust (mr. Harsh Vardhan Goenka Is A Trustee) 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Ishaan Goenka Trust (mr. Harsh Vardhan Goenka Is A Trustee) 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Avg Family Trust (mr. Anant Vardhan Goenka Is Atrustee ) 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Prism Estates Trust (mr. Harsh Vardhan Goenka Is A Trustee ) 1.0 (0.0%) Shareholding of Promoter and Promoter Group
Secura India Trust (mr. Harsh Vardhan Goenka Is A Trustee ) 2.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

RPG LIFE SCIENCES LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Jul 2023 12.0 Final 21 Jul 2023 Equity shares
14 Jul 2022 9.6 Final 15 Jul 2022 Equity shares
13 Aug 2021 7.2 Final 17 Aug 2021 Equity shares
24 Mar 2020 4.0 Interim 26 Mar 2020 Equity shares
22 Jul 2019 2.4 Final 24 Jul 2019 Equity shares
19 Jul 2018 2.4 Final 21 Jul 2018 Equity shares
13 Jul 2017 2.8 Final 17 Jul 2017 Equity shares
22 Mar 2016 1.6 Interim 24 Mar 2016 Equity shares
20 Jul 2015 0.8 Final 22 Jul 2015 Equity shares
11 Sep 2014 1.2 Final 15 Sep 2014 Equity shares
11 Sep 2014 0.8 Special 15 Sep 2014 Equity shares
11 Jul 2013 1.2 Final 15 Jul 2013 Equity shares
24 Jul 2012 0.8 Final 26 Jul 2012 Equity shares
14 Jul 2011 1.6 Final 18 Jul 2011 Equity shares
15 Jul 2010 1.44 Final 19 Jul 2010 Equity shares
30 Jul 2009 1.2 Final 01 Aug 2009 Equity shares
11 Aug 2008 1.2 Final 13 Aug 2008 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
28 Jun 2024 16.0 Final 28 Jun 2024 Equity shares
21 Jul 2023 12.0 Final 21 Jul 2023 Equity shares
14 Jul 2022 9.6 Final 15 Jul 2022 Equity shares
13 Aug 2021 7.2 Final 17 Aug 2021 Equity shares
24 Mar 2020 4.0 Interim 26 Mar 2020 Equity shares
22 Jul 2019 2.4 Final 24 Jul 2019 Equity shares
19 Jul 2018 2.4 Final 21 Jul 2018 Equity shares
13 Jul 2017 2.8 Final 17 Jul 2017 Equity shares
22 Mar 2016 1.6 Interim 24 Mar 2016 Equity shares
20 Jul 2015 0.8 Final 22 Jul 2015 Equity shares
11 Sep 2014 1.2 Final 15 Sep 2014 Equity shares
11 Sep 2014 0.8 Special 15 Sep 2014 Equity shares
11 Jul 2013 1.2 Final 15 Jul 2013 Equity shares
24 Jul 2012 0.8 Final 26 Jul 2012 Equity shares
14 Jul 2011 1.6 Final 18 Jul 2011 Equity shares
15 Jul 2010 1.44 Final 19 Jul 2010 Equity shares
30 Jul 2009 1.2 Final 01 Aug 2009 Equity shares
11 Aug 2008 1.2 Final 13 Aug 2008 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

RPG LIFE SCIENCES LTD Share Price

RPG Life Sciences Limited, formerly known as Searle India Limited, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).

RPG Life Sciences Limited was incorporated on March 29, 2007 with the name 'RPG Pharmaceuticals Limited' . During the year 2007-08, as per the Scheme of Arrangement, the Company acquired the Pharmaceuticals Business of Brabourne Enterprises Limited along with all assets and liabilities pertaining to that business with effect from April 2, 2007. On February 13, 2008, the name of the Company was changed to RPG Life Sciences Limited.

During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters.

During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments.

The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.

New products launched were Demator, Sizomax, Mela, Exinia and Mofetyl S during the year 2009-10. The Company strengthened its product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. It launched a new immunosuppressant product, Sirolimus in 2010.

New divisions were launched in highly growing chronic segments namely Cardiology and Diabetic (IMPULSE), NeurologyPsychiatry (EMPATHY) and Oncology (Neo-life). A new division ESSENTIA was also launched to cater to the Hospital sales segment in 2010-11. New products launched were Seretane 2 DT, Rabee 20, Pedimec, Minilactone, Alfalog, Demator, Naprosyn Gel, Lamotrigine dispersible tablets.

The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 2016-17. It acquired 7 brands from Sun Pharmaceuticals Limited, set up two new divisions viz. Urolife' catering to the urology therapy and Glodiance division catering to the Cosmetic Derma therapy in 2016-17.

In 2017-18, the Company launched brands Darbepoetin (Darba) and Rituximab (XMAB), in the post-transplant care space. Both the brands displayed robust performances in the first year of launch with Darba at third slot among competing Darbepoetin brands. Among the existing products, Immunotac and Arpimune range showed strong growth. In the Africa region, the Company expanded its business with first commercial supply in FY'18. It retained leadership position in Mauritius, through anti-diabetic range while in Egypt, immunosuppressant range remained the best alternative to the innovator brands in the post organ transplant care space.

During 2019, the Company focused on launching new products and driving active promotion in the immunosuppressant range of products and strengthened the oncology portfolio basket by introducing two new monoclonal antibodies. It launched a new product, T-JAKi (JAK Inhibitor) in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21. As a part of Life Cycle Management strategy of legacy products, Romilast BL and Aldactone T new line extensions were launched. Azoran 75 mg new line extension was launched in 2021. Naprosyn+ and Aldactone-F was launched in FY 2022.

In 2024, the Company launched a digital platform for comprehensive doctor engagement, RPGserv,' which integrates physical and digital capabilities. The Company's portfolio has been strengthened by new launches in Cardiovascular, Diabetology, Nephrology, Rheumatology, Oncology and Urology segments and by entering clinical Dermatology, Orthopedic and Critical Care segments in FY24-25.

Parent organization Goenka R P
NSE symbol RPGLIFE
Founded 2007
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of RPG Life Sciences Ltd?

Answer Field

RPG Life Sciences Ltd share price is for NSE ₹ 2,526.10 & for BSE ₹ 2,522.85 as on Jul 03 2025 11:28 AM.

What is the Market Cap of RPG Life Sciences Ltd Share?

Answer Field

The market cap of RPG Life Sciences Ltd for NSE ₹ 4,172.00 & for BSE ₹ 0.00 as on Jul 03 2025 11:28 AM.

What is the 52 Week High and Low of RPG Life Sciences Ltd?

Answer Field

The 52 Week High and Low of RPG Life Sciences Ltd for NSE is ₹ 2,974.95 and ₹ 1,539.95 and for BSE is ₹ 2,976.70 and ₹ 1,540.00.

What is 1 year return for RPG Life Sciences Ltd?

Answer Field

The 1 year returns on the stock has been 54.11%.

What is the P/E Ratio of RPG Life Sciences Ltd Share?

Answer Field

As on Jul 03 2025 11:28 AM the price-to-earnings (PE) ratio for RPG Life Sciences Ltd share is 22.59.

What is the PB ratio of RPG Life Sciences Ltd Share?

Answer Field

As on Jul 03 2025 11:28 AM, the price-to-book (PB) ratio for RPG Life Sciences Ltd share is 320.77.

How to Buy RPG Life Sciences Ltd Share?

Answer Field

You can trade in RPG Life Sciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy RPG Life Sciences Ltd Share on Bajaj Broking App?

Answer Field

To buy RPG Life Sciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “RPG Life Sciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|